Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 4717 to 4719 of 4719 entries
Sorted by: Best Match Show Resources per page
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.

European journal of cancer (Oxford, England : 1990)

Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S.
PMID: 34995900
Eur J Cancer. 2022 Jan 04;162:138-147. doi: 10.1016/j.ejca.2021.11.019. Epub 2022 Jan 04.

BACKGROUND: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised stage. For locally advanced recurrence or metastatic disease, DCF (docetaxel, cisplatin, 5-fluorouracil) demonstrated high efficacy and became one of the standard regimens....

Cite
Stouvenot M, Meurisse A, Saint A, et al. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. Eur J Cancer. 2022;162:138-147doi: 10.1016/j.ejca.2021.11.019.
Stouvenot, M., Meurisse, A., Saint, A., Buecher, B., André, T., Samalin, E., Jary, M., El Hajbi, F., Baba-Hamed, N., Pernot, S., Kaminsky, M. C., Bouché, O., Desrame, J., Zoubir, M., Smith, D., Ghiringhelli, F., Parzy, A., de la Fouchardiere, C., Almotlak, H., Vienot, A., Jacquin, M., Taieb, J., Nguyen, T., Vernerey, D., Borg, C., & Kim, S. (2022). Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. European journal of cancer (Oxford, England : 1990), 162138-147. https://doi.org/10.1016/j.ejca.2021.11.019
Stouvenot, Morgane, et al. "Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 138-147. doi: https://doi.org/10.1016/j.ejca.2021.11.019
Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. Eur J Cancer. 2022 Jan 04;162:138-147. doi: 10.1016/j.ejca.2021.11.019. Epub 2022 Jan 04. PMID: 34995900.
Copy Download .nbib Format: NLM
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.

Cancers

Shoji T, Tatsuki S, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T, Itamochi H.
PMID: 34885229
Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236120.

Ovarian cancer has the worst prognosis among gynecological cancers. In particular, clear cell and mucinous carcinomas are less sensitive to chemotherapy. The establishment of new therapies is necessary to improve the treatment outcomes for these carcinomas. In previous clinical...

Cite
Shoji T, Tatsuki S, Abe M, et al. Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236120.
Shoji, T., Tatsuki, S., Abe, M., Tomabechi, H., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., Baba, T., & Itamochi, H. (2021). Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers, 13(23), . https://doi.org/10.3390/cancers13236120
Shoji, Tadahiro, et al. "Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236120
Shoji T, Tatsuki S, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T, Itamochi H. Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236120. PMID: 34885229; PMCID: PMC8656608.
Copy Download .nbib Format: NLM
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.

Investigational new drugs

Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T.
PMID: 34495421
Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08.

Few clinical studies have been designed for elderly patients with locally advanced non-small cell lung cancer (NSCLC). We conducted a phase I study to evaluate the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy in elderly patients with locally advanced...

Cite
Omori S, Harada H, Mori K, et al. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2021;40(1):106-114doi: 10.1007/s10637-021-01155-w.
Omori, S., Harada, H., Mori, K., Hisamatsu, Y., Tsuboguchi, Y., Yoshioka, H., Morinaga, R., Daga, H., Kurata, T., & Takahashi, T. (2022). Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational new drugs, 40(1), 106-114. https://doi.org/10.1007/s10637-021-01155-w
Omori, Shota, et al. "Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 106-114. doi: https://doi.org/10.1007/s10637-021-01155-w
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08. PMID: 34495421.
Copy Download .nbib Format: NLM
Showing 4717 to 4719 of 4719 entries